Agios' Q1 Beat: AQVESME Launch Surges, SCD Filing on Track

What happened

Agios reported Q1 2026 mitapivat revenues of $20.7M, more than doubling from $8.7M a year ago, driven by the AQVESME thalassemia launch. The company disclosed 242 prescriptions written for AQVESME by March 31, indicating better-than-expected initial uptake despite the REMS program. Agios reiterated plans to submit a supplemental NDA for mitapivat in sickle cell disease in Q2 2026, keeping a key pipeline catalyst on schedule. The pipeline is advancing with two Phase 2 readouts for tebapivat expected in 2026, and the company maintains a $1.0B cash position. However, the cash burn remains elevated (from $1.3B to $1.0B in six months), and the SCD filing path remains uncertain given mixed Phase 3 data.

Implication

The AQVESME launch metrics (242 prescriptions) validate the thesis that REMS is not a structural barrier to adoption, reducing the probability of the bear scenario. Combined with the 2.4x revenue growth, Agios is demonstrating commercial execution in thalassemia. The planned SCD sNDA submission in Q2 2026 is a crucial catalyst; positive FDA feedback could dramatically expand the addressable market. However, cash burn accelerated to ~$300M annualized, trimming runway to ~3 years without revenue acceleration, limiting downside protection. Investors should watch for objective REMS certification metrics and SCD filing acceptance to confirm the positive trajectory.

Thesis delta

The Q1 update shifts the thesis toward a positive execution scenario: AQVESME's early script count exceeds cautious expectations, suggesting REMS friction is lower than feared. This reduces the probability of the bear case (30% to ~20%) and increases confidence in the base case of steady ramp. The SCD filing timeline remains intact but still carries binary regulatory risk.